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ABSTRACT The cardiac isoform of the ryanodine receptor (RyR2) from dog binds predominantly a 12.6-kDa isoform of the
FK506-binding protein (FKBP12.6), whereas RyR2 from other species binds both FKBP12.6 and the closely related isoform
FKBP12. The role played by FKBP12.6 in modulating calcium release by RyR2 is unclear at present. We have used cryoelectron
microscopy and three-dimensional (3D) reconstruction techniques to determine the binding position of FKBP12.6 on the surface of
canine RyR2. Buffer conditions that should favor the ‘‘open’’ state of RyR2 were used. Quantitative comparison of 3D recon-
structions of RyR2 in the presence and absence of FKBP12.6 reveals that FKBP12.6 binds along the sides of the square-shaped
cytoplasmic region of the receptor, adjacent to domain 9, which forms part of the four clamp (corner-forming) structures. The
location of theFKBP12.6 binding site on ‘‘open’’ RyR2appears similar, but slightly displaced (by 1–2nm) from that foundpreviously
for FKBP12binding to the skeletalmuscle ryanodine receptor thatwas in the buffer that favors the ‘‘closed’’ state. The conformation
of RyR2 containing bound FKBP12.6 differs considerably from that depleted of FKBP12.6, particularly in the transmembrane
region and in the clamp structures. The x-ray structure of FKBP12.6 was docked into the region of the 3D reconstruction that is
attributable to bound FKBP12.6, to show the relative orientations of amino acid residues (Gln-31, Asn-32, Phe-59) that have been
implicated as being critical in interactions with RyR2. A thorough understanding of the structural basis of RyR2-FKBP12.6
interaction should aid in understanding the roles that have been proposed for FKBP12.6 in heart failure and in certain forms of
sudden cardiac death.
INTRODUCTION
Ryanodine receptors (RyRs) are intracellular calcium chan-
nels that are found in many mammalian cell types, but they
are particularly enriched in the sarcoplasmic reticulum (SR)
of striated muscle where they play a key role in excitation-
contraction coupling (reviewed in Bers (1) and Fill and
Copello (2)). RyRs are the largest ion channels known, ex-
isting as homotetramers whose constituent subunit contains
;5000 amino acid residues. Of the three known isoforms of
RyR, isoform 2 (RyR2) is the main isoform in heart muscle
(3). RyRs often copurify with a tightly bound copy of a mod-
ulator protein, either a 12- or a 12.6-kDa isoform of FK506-
binding protein, an immunophilin that exhibits cis-trans
peptidyl-prolyl isomerase activity (2) and that can be con-
sidered as a second integral subunit of RyR. In mammalian
heart, RyR2-FKBP12.6 predominates over RyR2-FKBP12,
and this is particularly true of canine RyR2, which has very
low afﬁnity for FKBP12 (4–6). The stoichiometry of binding
has been known to be four moles of FKBP per mole of
tetrameric RyR (i.e., one mole FKBP per mole RyR subunit)
(4–6). RyR1s (skeletal muscle isoform) from various classes
of vertebrate were found to be associated with FKBP 12,
although in vitro experiments show that they are capable of
binding/exchanging with both isoforms of FKBP (7,8). The
precise role played by FKBP12/FKBP12.6 in the functioning
of RyRs is currently unclear and controversial, but it is of
intense interest, primarily because the proteins have been
implicated in the molecular mechanism of heart failure,
and possibly other arrhythmias, arising from mutations in
RyR2 (9–12).
Experiments conducted in vitro have shown that FKBP12
stabilizes the closed state of the skeletal muscle RyR, thereby
preventing inappropriate spontaneous channel openings
including, according to some studies, subconductance states
that occur in the absence of FKBP12 (13–18). Similar effects
of FKBP12.6 on RyR2 functioning have been reported in
some (19,20), but not all, laboratories (6,21).
FKBP12/FKBP12.6 has also been implicated in coordi-
nating the activities of RyRs that form contacts with one
another in the ordered arrays found at junctional interfaces of
the SRwith the sarcolemma/transverse tubule network (22,23).
In vitro, FKBP12 affects RyR1’s interactionswith the dihydro-
pyridine receptor, implying a possible role for FKBP12 inE-C
coupling (24,25). Another proposed function for FKBP12/
FKBP12.6 is to serve as an adaptor to bind the phosphatase
calcineurin to RyR1 andRyR2 (26,27), thereby enabling calcine-
urin to regulate the phosphorylation status of the receptor.
The role of the interaction of FKBP12/FKBP12.6 with
RyR in situ is even less clear. Depletion of FKBP12 from
skinned skeletal muscle ﬁbers interferes with E-C coupling
(28), and expression of recombinant mutated RyR1 that lacks
the capacity to bind FKBP12 in a skeletal muscle-derived
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cell line also affects E-C coupling (29). However, although
genetic knockout of FKBP12 is lethal in mice, skeletal
muscle is nevertheless functional, although the mice exhibit
severe cardiomyopathy. Conﬂicting results have been re-
ported for mice in which FKBP12.6 has been knocked out,
with one laboratory reporting cardiac hypertrophy in male
but not female mice (30), and another lab describing a more
severe phenotype in which susceptibility to heart failure and
sudden cardiac death are enhanced in both male and female
mice (12). Nevertheless, although the results of these studies
on FKBP12/FKBP12.6 knockout mice differ in detail, all
report abnormalities in cardiac function.
Marks and colleagues have proposed a provocative
mechanism for the progression of heart failure that involves
alterations in the FKBP12.6-RyR2 interaction (31). Specif-
ically, they ﬁnd that, due to the hyperadrenergic state typical
of heart failure, protein kinase A becomes overactive, and the
resulting hyperphosphorylation of RyR2 causes FKBP12.6
to dissociate from the receptor. FKBP12.6-depleted RyR2s
exhibit an abnormally high probability of the open state
during diastole that allows leakage of Ca21 from the SR; this
in turn reduces the amount of Ca21 that is available to induce
contraction during systole and might also trigger ventricular
tachycardia. This model for heart failure is currently being
tested, with both evidence for (11) and against (10) it being
reported. Intriguingly and seemingly in support of Marks’s
hypothesis (32,33), Yano and co-workers (34) report that a
drug, JTV519, shown previously to prevent FKBP12.6 from
dissociating from RyR2, is able to protect canine hearts from
cardiomyopathy in experimentally induced heart failure.
Recently, mutations in the human RyR2 have been asso-
ciated with rare forms of exercise-induced sudden cardiac
death, catecholaminergic polymorphic ventricular tachycar-
dia, and arrythmogenic right ventricular dysplasia (35–37).
Evidence that these mutated RyR2s are defective in their
interactions with FKBP12.6 has been described (9,12,38) but
these ﬁndings have been challenged (39).
Biochemical characterization of the FKBP12/FKBP12.6
binding site on RyRs has been the subject of numerous in-
vestigations. For the RyR1 and RyR3 isoforms, evidence
points to a conserved valyl-prolyl motif (amino acid residues
2461 and 2462 in RyR1) as being required for binding of
FKBP12/FKBP12.6 (40,41). The FKBP12 binding site has
also been mapped on the physical structure of RyR1 to a re-
gion at the edge of the cytoplasmic region of the receptor by
cryoelectron microscopy (cryo-EM) and three-dimensional
(3D) reconstruction of isolated RyR1-FKBP12 complexes
(42–44). For RyR2 there is an analogous isoleucyl-prolyl
sequence (amino acid residues 2427 and 2428) that has been
implicated in binding FKBP12.6 (31), but other studies have
additionally implicated contributions from other regions of
the RyR2 sequence (45–47). Chen and colleagues ﬁnd that
mutation of Ile-2427 or Pro-2428 does not affect FKBP12.6
binding (46) and, further, that an amino-terminal polypeptide
fragment encompassing residues 1–1855 derived from RyR2
is sufﬁcient for binding of FKBP12.6 (47). In light of these
apparent differences between the modes of FKBP12 and
FKBP12.6 binding to respective RyRs, and also because of
the above-mentioned potential importance of the RyR2-
FKBP12.6 complex in heart disease, we decided to investigate
the FKBP12.6 binding site on RyR2 by 3D cryomicroscopy.
MATERIALS AND METHODS
Immunoafﬁnity puriﬁcation of RyR2
An isoform-speciﬁc RyR2 rabbit polyclonal antibody was developed using
a synthetic peptide whose sequence corresponded to 11 amino acids 4418–
4429 of rabbit RyR2 (48). The immunizing protocol and afﬁnity puriﬁcation
of sequence-speciﬁc antibodies are similar to that described elsewhere (49).
Afﬁnity-puriﬁed RyR2-speciﬁc antibody was prebound to an immobi-
lized protein A/G matrix by incubating for 1/2 h at room temperature with
gentle mixing. Afﬁnity-puriﬁed antibody (200–400 mg) was admixed with
protein A/Gmatrix (;200 ml packed bed volume). RyR2-enriched dog heart
SR, prepared according to the method described by Chamberlain and co-
workers (50), was used for the puriﬁcation of RyR2. Cardiac SR (100 mg)
was solubilized at 6.0 mg/ml in buffer A (20 mM Na2PIPES, pH 7.2, 0.6 M
NaCl, 0.1 mM EGTA, 0.2 mM CaCl2, 5.0 mM Na2AMP, 2.0 mM DTT, and
0.6% CHAPS (w/v)/0.3% SBL) for 90 min at 4C with gentle mixing. The
mixture was then centrifuged at 50,000 g for 30 min at 4C to remove
insoluble material. The supernatant was diluted fourfold with dilution buffer
(Buffer B) containing 20.0 mMNa2-PIPES, pH 7.2, 0.1 mM EGTA, 0.2 mM
CaCl2, 5.0 mM Na2AMP, 2.0 mM DTT, and 0.3 M sucrose and preabsorbed
with 50 ml of the preequilibrated protein A/G matrix for 15 min at 4C with
gentle mixing to remove nonspeciﬁcally bound components. After sedi-
menting at low speed in the cold to remove the matrix, the supernatant was
transferred to another container, and RyR2 was selectively immunoadsorbed
by incubating, with gentle mixing overnight at 4C, with the calculated
amount of prebound RyR2-speciﬁc antibody, i.e., prebound to protein A/G
matrix. The prebound RyR2 Ab-protein A/G matrix had been preequili-
brated with Buffer B (containing 0.15 M NaCl, 0.15% CHAPS/0.075%
SBL) for 30 min at 4C before addition of RyR2. The amount of antibody
matrix used to bind RyR2 was determined by the ryanodine binding activity
of the cardiac microsomes. A three- to fourfold excess of antibody, i.e., molar
ratio of antibody/total RyR binding equivalents was used. The immune com-
plex containing the RyR2 was then sedimented at low speed and was washed
sequentially, ﬁrst with Buffer B containing 0.15 M NaCl, and 0.5% CHAPS/
0.25% SBL, second with Buffer B containing 0.5 M NaCl and 0.5%
CHAPS/0.25 SBL, and third with Buffer B containing 0.1 M NaCl and 0.5%
CHAPS/0.25% SBL. The elution of the RyR2 was carried out with Buffer B
containing 20 mM PIPES (pH 7.2), 0.4 M NaCl, 2 mM DTT, 0.6% CHAPS/
0.3% SBL, 0.1 mM EGTA, 0.2 mM CaCl2, 5 mM Na2AMP and excess of
epitope peptide (3.0 mg/ml). The eluate was collected and the pellet was
washed again with elution buffer without epitope peptide (posteluate). The
elution procedure takes ;1 h in the cold room (4C). This elution protocol
should favor the open state of RyR2 (51). The eluate and posteluate were
quick-frozen in liquid nitrogen and stored at 80C. All the buffers used in
the preparations contained the protease inhibitors, leupeptin (1.0 mg/ml),
aprotonin (1.0 mg/ml), and phenyl-methylsulfonyl ﬂuoride (40 mM).
SDS-PAGE and Western blot analysis
Dog heart SR, i.e., the source of RyR2 and eluates from the immunoafﬁnity
matrix, and RyR2-FKBP12.6 complexes were analyzed by SDS-PAGE and
visualized by Coomassie blue staining. For Western blot analysis after SDS-
PAGE, the proteins were transferred to an Immobilon-P membrane for 1 h at
24 mA constant current in blot transfer buffer (48 mM Tris, 39 mM glycine,
1.3 mM SDS, pH 9.2) using Trans-Blot SD Semi-Dry Electrophoretic
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Transfer Cell (Bio-Rad, Hercules, CA). The vacant binding sites on the mem-
brane were blocked by incubating the membrane in wash buffer (10 mM
Tris-Cl, pH 8.0, 0.55 M NaCl, and 0.05% Tween-20) containing 5% nonfat
dry milk protein for 1 h. Then the membrane was incubated with the RyR2
or FKBP12-speciﬁc antibody in blocking buffer for 1 h. The membrane was
washed three times with wash buffer and then incubated with secondary
antibody (goat anti-rabbit IgG) conjugated to alkaline phosphatase in
blocking buffer. The membrane was again washed three times with wash
buffer and developed with nitroblue tetrazolium (NBT) and 5-bromo-4-
chloro-3-indoyl phosphate (BCIP) substrates.
Protein determination
Small quantities of proteins such as puriﬁed receptor and puriﬁed FKBP12.6
were determined by scanning densitometry. Densitometry was carried out
using an automated gel analysis plus image processing system (Technology
Resources, Nashville, TN) on the RyR2 band after separation in 7.5%
resolving gel (SDS-PAGE) and FKBP12.6 in 12.5% resolving gel and
staining with Coomassie blue and making use of an HP Scan Jet 4p Scanner,
Hewlett Packard and Visioneer PaperPort Software program. Bovine serum
albuminwas applied to the SDS-PAGEas the protein standard for calibration.
[3H]Ryanodine binding
Routine high afﬁnity ryanodine binding was determined at 60 nM ryanodine.
Ryanodine binding to particulate fractions made use of sedimentation to
separate bound from free ryanodine as previously described (49). High
afﬁnity ryanodine binding parameters were measured by ryanodine binding
isotherms using [3H]ryanodine (;15,000 cpm/pmol, obtained from DuPont,
NEN, Boston, MA). The binding assay for solubilized fractions was carried
out by polyethylene glycol (PEG) precipitation using equine g-globulin as
carrier protein. The samples, 10 ml aliquots, were incubated for 1 h at room
temperature in 50 ml of buffer containing 10 mM HEPES-KOH, pH 7.4, 1.0
M KCl, 25 mM CaCl2, 2 mM DTT, and 5.0 mg/ml g-globulin, and 60 nM
[3H]ryanodine. Then PEG (12.5 ml of 25.0%, w/v) was added to the assay
mixture and mixed thoroughly using a vortex mixer, and the free ligand was
separated from the bound by sedimenting the pellet in a Beckman (Fullerton,
CA) TL-100.1 rotor at 95,000 rpm for 15 min at 4C. The supernatant was
removed by aspiration, and the pellets were rinsed twice with water and then
resuspended in 0.2 ml of water. The suspensions were transferred to
scintillation vials, in 5.0 ml of Cytoscint (ICN, Cleveland, OH) and the
radioactivity was measured in a Beckman LS 5000TD scintillation counter.
Nonspeciﬁc binding was measured in the presence of 20 mM cold ryanodine.
Source of FBKP12.6
Human recombinant FKBP isoform 12.6 was prepared as described earlier
(52) and puriﬁed by high-performance liquid chromatography using a TSK
G3000SW column (6).
Preparation of RyR2-FKBP12.6 complexes for
cryoelectron microscopy
Puriﬁed RyR2 (0.15 mM) was incubated at room temperature (23C) for 45
min with FKBP12.6 (4.7 mM), in either the absence or presence of 50 mM
FK506 (19,44). The elution buffer of the RyR2, containing 20 mM PIPES
(pH 7.2), 0.4 M NaCl, 2 mM DTT, 0.6% CHAPS/0.3% SBL, 0.1 mM
EGTA, 0.2 mM CaCl2, 5 mM Na2AMP, that favors an open state of
receptor, was used in preparation of the above RyR2-FKBP12.6 complexes.
Cryo-EM grids containing frozen-hydrated protein were prepared as de-
scribed previously (53). We refer to the complex of RyR2 that was incubated
with excess FKBP12.6 as ‘‘RyR2 (1FKBP)’’ and the drug-treated sample,
which dissociates FKBP12.6 from RyR2, as ‘‘RyR2 (FKBP)’’.
Cryoelectron microscopy and image processing
Cryoelectron micrographs were recorded at 38,8003 magniﬁcation on a
Philips (Eindhoven, The Netherlands) EM 420 transmission electron mi-
croscope operated at 100 kV and equippedwith a low-dose kit and a GATAN
(model 626) cryo-transfer holder. The defocus range for micrographs was
2.0–2.5 mm underfocus. Some micrographs were recorded with the grid at 0
tilt and others with the grid tilted by 30, so as to obtain adequate sampling
of orientations of the RyR complexes. Micrographs were selected for image
processing as described previously (53) and then digitized on a Eurocore Hi-
Scan microdensitometer (Saint-Denis, France) with a 25-mm step size,
corresponding to 5.23 A˚ on the object scale. For RyR2 (1FKBP), 2095
particle images, and for control RyR2 (FKBP), 1227 good particle images
were selected, after manual screening of images. Reduction of ‘‘bad’’
particles (53) was done by setting the threshold of cross correlation so as to
eliminate 25% of the particles, thereby improving the homogeneity of the
data set. SPIDER software (54) was implemented to obtain the 3D
reconstruction by the projection-matching technique (53,55). The ﬁnal
resolution of both reconstructions was estimated to be 33 A˚ by Fourier shell
correlation, with the cutoff of 0.5 (56). To obtain the FKBP12.6 density
present in RyR2 (1FKBP12.6), a difference map was computed by
subtracting the 3D map of RyR2 (FKBP12.6) from the RyR2 (1FKBP12.6)
map, and density mass obtained was displayed at the same threshold as the 3D
maps of RyR2 complexes. The corresponding cryo-density for FKBP12.6
was ﬁtted with x-ray structure of FKBP12.6, ﬁltered to the same resolution
as 3D of RyR2. Since the FKBP12.6 x-ray structure is a complex with
rapamycin, coordinates of rapamycin were removed from the pdb ﬁle and
only FKBP12.6 coordinates were used for our docking that was done by
using ‘‘O’’ software (57), and visualized by using ‘‘Ribbons’’ (58) and
‘‘IRIS EXPLORER’’ (Numerical Algorithms Group, Downer Grove, IL).
RESULTS
Biochemical and functional characterization
of puriﬁed RyR2 from dog heart
sarcoplasmic reticulum
We have described a new method of puriﬁcation of RyR2
from dog heart SR using an afﬁnity-puriﬁed sequence-
speciﬁc selective antibody to RyR2. The binding of RyR2 to
the Ab/protein A/G matrix was similar to RyR3 as described
earlier (49). The elution of puriﬁed RyR2 from the immune
complex with the use of peptide epitope yielded the puriﬁed
eluate of RyR2 of high purity as viewed by SDS-PAGE,
speciﬁc ryanodine binding, and cryo-EM. Western blot anal-
ysis conﬁrmed that the peptide eluates from the immune pre-
cipitate contained highly puriﬁed RyR2. The yield of RyR2
as determined by densitometry was ;25–30 mg protein,
from;100 mg of starting dog heart SR. The yield can be im-
proved by using more afﬁnity-puriﬁed antibody to purify the
RyR2. The amount used is a practical compromise.
The ryanodine binding of the puriﬁed RyR2 receptor was
300–355 pmols/mg of protein measured at 60 nM ryanodine.
This is about a 110-fold enrichment from the starting dog
heart SR, which shows high afﬁnity binding of;2.5 pmoles/
mg protein. This value indicates that the RyR2 is highly
puriﬁed and functional with respect to ryanodine binding.
Homogeneously pure and functional RyR2, calculated from
the known sequence, has a predicted Bmax ;450 pmols/mg
protein. Cryo-EM further conﬁrmed that the RyR2 puriﬁed
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by the immunoafﬁnity method was of high purity and was
structurally intact (see Results below).
The buffer conditions (see Materials and Methods) used in
this study is expected to favor the open state of the receptor
(51,59). We chose these conditions, as opposed to ‘‘closed’’
conditions (closed conditions include submicromolar [Ca21],
no nucleotide (51), such as were used in our previous cryo-
EM analysis of RyR2 (53)), because the structural integrity
of the receptors, as judged from the appearance of the images,
appeared to be better when the receptor was isolated in the
presence of activating ligands (such as nucleotide or epitope,
see Meissner (51) for details). We previously noted a similar
improved structural stability under open as compared to closed
buffer conditions for ryanodine receptor isoform, RyR3 (59).
The best results were obtained when we incubated puriﬁed
RyR2with an excess of FKBP12.6 (ratio of RyR2/FKBP12.6 to
be;1:30) in the presence and in the absence of the FKBP12.6-
dissociating drug FK506, respectively (see Materials and
Methods and also see Kaftan et al. (19)), receptors prepared
by these two conditions will henceforth be referred to as
RyR2 (FKBP) and RyR2 (1FKBP)). Conﬁrmation that the
desired complexes were obtained was achieved by immu-
noprecipitation using RyR-speciﬁc antibody followed by
Western blotting to detect coprecipitated FKBP12.6 (see
Supplemental Fig. S1).
Structure of the RyR2-FKBP12.6 complex
Structures of RyR2 (1FKBP12.6) and RyR2 (FKBP12.6)
complexes were obtained using cryo-EM and image pro-
cessing as described in Materials and Methods. The overall
appearances of the resulting 3D reconstructions for RyR2
(1FKBP) and RyR2 (FKBP) are illustrated as surface re-
presentations (Fig. 1, A and B), which are displayed at
a threshold to match the molecular mass of receptor by
taking into account the protein density of 1.22 g cm3 (60).
Similarly, the difference map was displayed at the same
threshold as the receptor (Fig. 1 B), and each of the densities
attributed to FKBP12.6 corresponds approximately to the
molecular mass of FKBP12.6.
As described previously for RyR2, as well as for RyR1 and
RyR3, the receptor comprises two main structural compo-
nents: a transmembrane assembly representing ,1/5 of the
total mass, and a multidomain cytoplasmic assembly (Fig. 1, A
and B, domains labeled 1–10) representing the main mass
(61,62). Not surprisingly, the reconstructions shown in Fig. 1
are similar to previous reconstructions ofRyRs, but they differ
subtly from one another in several regions that we believe are
of signiﬁcance. As described below, not all of the differences
appear to be attributable to extra mass density of the bound
FKBP12.6 expected to be present in the RyR2 (1FKBP) but
not in RyR2 (FKBP); we infer that these arise from con-
formational differences present between the two complexes.
One major difference between the RyR2 (1FKBP) and
RyR2 (FKBP) structures occurs in domain 6, which in
RyR2 (1FKBP) appears to be more extended (‘‘stretched’’)
in the vertical direction (when the receptor is viewed from
the side) (Fig. 1, A and B, rightmost panels). Also apparent
are alterations in the transmembrane assembly; these give
the appearance of a ;4 rotation between RyR2 (1FKBP)
and RyR2 (FKBP) when the structures are viewed from the
SR-interacting face (Fig. 1, center panels). Both of these
differences are similar to structural differences between pu-
tatively open and closed forms of RyR1 (and also of RyR3)
that have been described previously (59,63). Thus, RyR2
(1FKBP) appears similar in conﬁguration to the open forms
of RyR1 and RyR3, whereas RyR2 (FKBP) resembles the
closed form of the receptors. In an earlier study we
FIGURE 1 Surface representations of 3D cryo-EM
reconstructions of RyR2 with and without bound
FKBP12.6. (A) The 3D map of RyR2 (1FKBP), obtained
by assembly in vitro of puriﬁed RyR2 incubated with
FKBP12.6 alone, and (B) the 3D map of RyR2 (FKBP),
obtained by incubating RyR2 with FKBP12.6 and excess
FK506, with the superimposed map of difference density
(shown in blue), as obtained by subtracting the 3D map of
RyR2 (FKBP) from that of RyR2 (1FKBP). In panel A,
arrows point to the extra density in RyR2 (1FKBP12.6)
that accounts for the FKBP12.6 mass that is enhanced in
the difference map shown in panel B. The 3D volumes for
the two conditions are each shown in three views: left,
cytoplasmic view; middle, SR junctional face; and right,
side view. Abbreviation: TA, transmembrane assembly.
Numerals refer to established nomenclature of domains.
Scale bar ;100 A˚.
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determined a 3D reconstruction for RyR2 under conditions
that favored the closed state of the channel (53), and that re-
construction was similar to the RyR2 (FKBP) reconstruc-
tion obtained in this study, with respect to the conﬁgurations
of domain 6 and the transmembrane assembly as has been
shown for the closed state of RyR3 (59) (thumbnail at lower
left of Fig. 2). Thus, it appears that RyR2 (FKBP) assumed
a conformation resembling that of the closed conformation.
This is an unanticipated result, since both the RyR2 (1FKBP)
and RyR2 (FKBP) reconstructions were computed from
specimens under buffer conditions that should have favored
the open form of the receptor (see Discussion for further
elaboration of this interpretation).
The differences between the two reconstructions that were
discussed above, which we attribute to conformational differ-
ences between RyR2 (1FKBP) and RyR2 (FKBP), com-
plicate the localization of the bound FKBP12.6, which was
the major objective of this study. Nevertheless, a difference
map (Fig. 1 B, blue density), obtained by subtraction of
the RyR2 (FKBP) volume from that of RyR2 (1FKBP),
shows that there are two main sites of positive difference be-
tween the reconstructions (representing mass present in RyR2
(1FKBP) that is absent from RyR2 (FKBP)), each
repeated four times as expected for the tetrameric receptor.
The difference due to the extension of domain 6 is already
discussed, as well as a discrete difference maximum that
maps to the interface between domains 3 and 9. The latter
difference certainly corresponds to the bound FKBP12.6 (for
justiﬁcation see Discussion). The apparent overall volume of
the difference attributed to FKBP12.6 is approximately that
expected for a 12.6-kDa protein.
DISCUSSION
RyR2 puriﬁcation and Cryo-EM
It is known that Cryo-EM density maps are crucial in elu-
cidating the details of interactions and structural/functional
conformational changes associated with ligand binding even
for complexes such as ribosomes, for which atomic models
have been solved (64,65). In this study, a new method of
puriﬁcation of canine heart RyR2 that makes use of an
afﬁnity-puriﬁed polyclonal antibody directed against an 11
amino acid peptide epitope of RyR2 (amino acid residues
4418–4429) has been described. The heart SR is solubilized
with CHAPS, and the RyR2 is immunoprecipitated using the
afﬁnity-puriﬁed polyclonal antibody. Puriﬁed RyR2 is then
gently eluted using peptide epitope, as previously described
for the puriﬁcation of RyR3 (49). The advantages of the new
procedure for RyR2 are that it is less laborious than methods
employing gradient centrifugation and it yields receptors that
are functional and structurally intact for cryo-EM and image
processing.
Location of FKBP12.6 binding sites on RyR2
Evidence from previous biochemical studies have shown
that maximally ;4 moles of FKBP12.6 bind per mole of
RyR2 tetramer (5,6). Here we have determined the location
of FKBP12.6 binding on the structure of RyR2 by cryo-EM
and single-particle 3D reconstruction techniques. This was
accomplished by obtaining and comparing two independent
3D reconstructions, one under conditions where FKBP12.6
should bind to the receptor, and the other in the presence of
the drug FK506, which should result in the dissociation of
FKBP12.6 from the receptor. The complexes were prepared
in buffers containing Ca21 and nucleotide, which are ex-
pected to favor the open state of the receptor. Unexpectedly,
several differences were found between the two reconstruc-
tions that complicated a straightforward interpretation of the
FKBP12.6-binding location. Nevertheless, we attribute one
of the two principal differences, the one occurring near the
junction of domains 9 and 3, to bound FKBP12.6. Since RyR2
is a homotetramer, this difference is repeated four times in the
reconstruction (Fig. 1 B).
We are conﬁdent that our interpretation of FKBP12.6’s
location is correct for the following reasons. First, this site is
located in the same vicinity as the site where the homologous
binding protein, FKBP12, binds to RyR1 (44). Since there is
high homology between the two FK506-binding protein
isoforms (66) as well as between the two RyR isoforms (3), it
is likely that the mode of binding will be similar in the two
cases. Second, the location of amino acid Thr-1874 is on
domain 9 of RyR2, and evidence has been reported that the
FKBP12.6 binding site involves amino acid residues in this
vicinity, speciﬁcally residues 1815–1855 (47). Those ﬁnd-
ings are consistent with our assignment of the FKBP12.6
binding site because the Thr-1874 site is within;30 A˚ of the
FIGURE 2 3D maps of RyR2 (1FKBP) and RyR2 (FKBP) shown at
two different contour levels with a previously determined structure of RyR3
(59). (A) Two superimposed volumes of RyR2 (1FKBP12.6) are shown,
one in semitransparent pink and the other as solid pink. For comparison,
the ‘‘open’’ RyR3 structure is shown as a thumbnail to the lower left. (B)
Similarly, as in panel A, two volumes of RyR2 (FKBP12.6) are super-
imposed, one shown in solid red and the other as semitransparent red. The
comparative structure of RyR3 in the ‘‘closed’’ state is shown as a thumbnail
to the lower right. For both panels A and B, the semitransparent structures are
displayed at the same threshold as in Fig. 1, whereas the solid densities of
both complexes are shown at a higher threshold such that their total volume
is ;1/4 of the semitransparent map. Note the similar conformations of the
domains ‘‘6’’ in (RyR2 -FKBP12.6) complexes and changes in trans-
membrane assembly that correlate to RyR3 volumes, respectively. Scale bar
;100 A˚.
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FKBP12.6 location reported here. Third, the density differ-
ences between RyR2 (1FKBP) and RyR2 (FKBP) that we
do not believe are contributed by bound FKBP12.6 can be
explained as arising from conformational differences be-
tween the RyR2 structures in the two reconstructions (dis-
cussed below).
The FKBP12.6 binding site on RyR2 is similar to that
found previously for FKBP12 binding to RyR1 (45,46), but
the two sites appear to differ slightly in location by 10–20 A˚
(for a comparative ﬁgure refer to Supplemental Fig. S2).
Although this apparent shift could be due to actual differ-
ences in the modes of binding of FKBP12.6 and FKBP12, as
has been hypothesized recently on the basis of apparent dif-
ferences in the binding speciﬁcities of the two proteins (46,47),
it is premature to assign any signiﬁcance to this difference
for the following reasons. Our previous study of the RyR1-
FKBP12 complex was performed under conditions that
favored the ‘‘closed’’ state of RyR1, whereas this study of
RyR2 (1FKBP) was done under conditions promoting the
‘‘open’’ state. Therefore, the apparent difference in the
binding-site location of FKBP12 and FKBP12.6 could be due
to conformational differences between open and closed states
of the receptors; indeed, movements of domain 9 (a domain
which contributes to, or is adjacent to, the FKBP binding
sites) in transitions between closed to open states have been
documented previously for RyR1 and RyR3 (59,67). Alter-
natively or additionally, inherent structural differences between
the RyR1 and RyR2 isoforms could account for the differ-
ence in the binding-site locations; in this regard it should be
noted that one of the three regions in which the receptor
isoforms’ sequences are highly divergent (speciﬁcally, diver-
gent region 3, involving RyR1 amino acid residues 1872–
1903) is probably near to the FKBP binding region (47).
Currently, the resolutions of our reconstructions limit our
ability to uniquely ﬁt the atomic structure of an FKBP12.6-
rapamycin complex (68) into our map. We have therefore
manually placed a ribbon representation of the structure of
FKBP12.6 into the cryo-EM density map in an orientation
that ﬁts the difference density reasonably well and which is
consistent with available biochemical information (Fig. 3).
The docking places amino acid residues Gln-31 and Asn-32
of FKBP12.6, which have been shown by site-directed
mutagenesis to be important in FKBP12.6’s interaction with
RyR2 (8), near the surface of RyR2 (Fig. 3). Phe-59, which
has also been implicated in the FKBP12.6-RyR2 interaction,
lies in the crystal structure at the base of a hydrophobic
cavity that binds the drugs FK506 and rapamycin. Although
the drug-binding pocket faces RyR2 in our ﬁtting, Phe-59
appears to be ;10 A˚ from the apparent surface of RyR2;
thus, its role in the interaction of FKBP12.6 with RyR2 may
be indirect. Two other residues that are associated with the
drug-binding region and that have been proposed to con-
tribute to binding speciﬁcity are Ala-63 and Ile-90 (68), and,
similarly to Phe-59, they appear displaced from RyR2’s sur-
face. If we assume that our docking of FKBP12.6 is approx-
imately accurate, some of the amino acid residues immediately
downstream of Asn-32 and extending to approximately Arg-
42, which make up a b-sheet and a surface-exposed loop
(Fig. 3), could further contribute to the interaction with RyR2.
Future studies by site-directed mutagenesis are needed to test
this prediction. Note that some of these residues are sep-
arated from Gln-31 and Asn-32 by up to 20 A˚. Thus, the
binding ‘‘footprint’’ of FKBP12.6 on RyR2 is sufﬁciently
large to allow several separated regions of RyR2’s amino
acid sequence to be involved in binding FKBP12.6 (e.g., Ile-
Pro residues 2427 and 2428 as well as the region contained
within residues 1815–1855), as proposed by Zhang and col-
leagues (47).
Structure of the RyR2 under open state conditions
Both the RyR (1FKBP) and RyR (FKBP) 3D reconstruc-
tions were determined using buffer conditions that should
favor the open state of the receptor. The reconstruction of
RyR (1FKBP) indeed displays some structural features that
differ from our previous reconstruction of RyR2 prepared
under closed conditions (53) and that are characteristic of the
open forms that have been reconstructed previously for the
FIGURE 3 Manual docking of FKBP12.6 atomic
structure (68) into the 3D density difference map. To
the left, a reconstruction of the RyR2 (FKBP)
complex is shown with the difference density map
(blue), attributed to FKBP12.6, superimposed (blue;
also see Fig. 1). To the right is an enlargement of one
of the four FKBP12.6 differencemasses with a ribbon
representation of the FKBP12.6 atomic structure (68)
docked inside it. To obtain an optimal ﬁtting, the
difference map density is displayed at a slightly
lower threshold as that shown in Fig. 1 B, keeping the
maximum limit of the difference density close to the
known molecular mass of FKBP12.6. Side chains of
residues of interest (Ala-63, Phe-59, Ile-90, Gln-31,
and Asn-32) are shown in dark blue (see text).
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other receptor isoforms, RyR1 (67) and RyR3 (59). Sur-
prisingly, however, the reconstruction of RyR2 (FKBP)
does not show such characteristics; instead, its 3D structure
more closely resembles structures of RyR isoforms, in-
cluding RyR2, in the closed state (53,59,67). Two of the main
features that distinguish open from closed receptors (which
can be seen by comparing Fig. 2 A (RyR (1FKBP), puta-
tively open) with Fig. 2 B (RyR2 (FKBP), putatively
closed)) are an elongation of cytoplasmic domain 6 along
a direction approximately parallel to the receptor’s fourfold
symmetry axis (Fig. 2, A and B, rightmost panels) and a
splaying apart of elongate high-density regions within the
transmembrane region. In Fig. 2, these changes are illustrated
for RyR2-FKBP12.6 complexes and for reference, open and
closed forms of RyR3 from previous work (59) are also
shown (as thumbnails). It should be appreciated that the con-
formational changes associated with domain 6 are distant,
well over 100 A˚, from the cytoplasmically exposed entrance
to the ion channel, which is presumably located near the
center of the receptor, near the junction of the cytoplasmic
and transmembrane regions.
Signiﬁcance of RyR2 (2FKBP) structure
An unexpected result was that the 3D reconstruction of
RyR2 (FKBP) resembles more closely a reconstruction of
the closed state of the receptor, even though open-promoting
conditions were used for the experiment (69). On the other
hand, the reconstruction of RyR (1FKBP) does exhibit fea-
tures characteristic of the open state (see above), as expected.
The main functional effect of FKBP12.6/FKBP12 binding
to RyR2/RyR1 is frequently described as a stabilization of
the closed state of the receptor, because when FKBP12.6/
FKBP12 is removed from the receptors they periodically
open for brief intervals in the absence of channel activators
(70). If destabilization of the closed state is indeed the main
functional effect of removing FKBP12.6, then one might
have expected the 3D map of RyR2 (FKBP) to be in the
open state.
How, then, do we account for our ﬁnding that the RyR2
(FKBP) structure resembles the closed state? We hypoth-
esize that this structure depicts a state of the receptor that
is neither fully open nor closed. An effect of removal of
FKBP12/FKBP12.6 from RyR1/RyR2 is that frequently
when channel openings do occur after addition of channel
activators, the conductance of the channels is reduced to
a constant fraction of the fully open state (15,19). However,
these subconductance states have not been observed by all
workers (21), and it has been suggested that such states
might arise due to a secondary direct interaction of FK506
(or rapamycin) with RyR1/RyR2, particularly in cases where
RyR2 is exposed for extended durations (.20 min) or to
elevated levels of the drug (50 mM); both of these conditions
applied in our study (21). Our working hypothesis is that the
3D structure of FK506-treated RyR2 in the presence of
channel activators depicts the receptor in a conﬁguration that
corresponds to a subconductance state, rather than to the
open state; if this is so, then our results indicate that the
structure of this subconductance state is more similar to that
of the closed than to that of the open state.
In summary, we have found that 1) FKBP12.6 binds to
RyR2 at a site close to that found on RyR1 for FKBP12, and
2) RyR2 depleted of FKBP12.6 by drug treatment has a
different conformation from that with FKBP12.6 present.
Future studies of additional RyR-FKBP complexes and at
higher resolution will be necessary to determine 1) whether
there are any signiﬁcant differences in the binding modes of
FKBP12.6 and FKB12 to RyR isoforms, and 2) the precise
conformational changes of RyR2 induced by FKBP12.6
depletion.
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